CRMD logoCRMD
CorMedix Inc

22,551
Loading...
Loading...
News
all
press releases
IMVT Stock Up 11% on Upbeat Batoclimab Hyperthyroidism Study Results
Immunovant stock jumps 11% after new batoclimab study results showed durable thyroid hormone control in Graves' disease patients.
Zacks·4d ago
News Placeholder
More News
News Placeholder
Cytokinetics Gains on Positive Late-Stage Cardiomyopathy Study Results
CYTK shares soar 40% after phase III MAPLE-HCM results showed that aficamten outperformed metoprolol in obstructive HCM.
Zacks·5d ago
News Placeholder
Wall Street Analysts Think CorMedix (CRMD) Could Surge 32.04%: Read This Before Placing a Bet
The mean of analysts' price targets for CorMedix (CRMD) points to a 32% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Zacks·5d ago
News Placeholder
Editas Nominates EDIT-401 as Lead In Vivo Therapy for High Cholesterol
EDIT nominates EDIT-401, a one-time in vivo gene editing therapy, as its lead pipeline candidate to cut the risk of elevated cholesterol.
Zacks·5d ago
News Placeholder
Is DefenCath Sufficient to Support CorMedix's Long-Term Growth Path?
CRMD's DefenCath, its only revenue source, posts $78.8M in sales in H1 2025, with exclusivity through 2033 fueling growth potential.
Zacks·6d ago
News Placeholder
ALNY/RHHBY's Zilebesiran to Enter Phase III After Third Phase II Win
Alnylam and Roche report positive phase II KARDIA-3 results for zilebesiran in high-risk hypertension patients, fueling momentum for a phase III study.
Zacks·7d ago
News Placeholder
Biogen Secures FDA Nod for Subcutaneous Maintenance Dosing of Leqembi
BIIB wins FDA approval for Leqembi Iqlik, a fast, subcutaneous option for early Alzheimer's patients transitioning from IV infusions.
Zacks·7d ago
News Placeholder
J&J Ends Imaavy Development in Rheumatoid Arthritis Post Study Failure
JNJ halts Imaavy's rheumatoid arthritis program after trial results showed no added benefit over existing therapy.
Zacks·10d ago
News Placeholder
OTLK Stock Crashes 54% as FDA Issues Second CRL for Eye Disease Drug
Outlook Therapeutics stock plunges 54% after the FDA rejects ONS-5010 BLA again, citing lack of efficacy data in confirmatory study.
Zacks·10d ago
News Placeholder
INO Stock Soars as FDA Backs Rolling BLA for Rare Lung Disease Drug
Inovio stock surges 21% after the FDA gives green light to begin a rolling BLA for its RRP drug INO-3107, with plans to seek priority review.
Zacks·11d ago

Latest CRMD News

View

Advertisement. Remove ads.

Advertisement. Remove ads.

Advertisement. Remove ads.